<DOC>
	<DOCNO>NCT01816776</DOCNO>
	<brief_summary>The primary purpose prospective , multicenter , randomize trial evaluate safety effectiveness therapy deliver remedē® system subject moderate severe central sleep apnea optimal medical management , compare outcome randomize control subject receive optimal medical management implant inactive remedē® system .</brief_summary>
	<brief_title>Respicardia , Inc. Pivotal Trial remedē System</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Central</mesh_term>
	<criteria>1 . At least 18 year age 2 . Central Sleep apnea confirm core lab analysis PSG EEG within 40 day schedule implant : Apnea/Hypopnea Index ( AHI ) great equal 20 ; Central Apnea Index ( CAI ) least 50 % apnea , least 30 central apnea event ; Oxygen Desaturation Index ( OAI ) less equal 20 % total AHI 3 . Medically stable 30 day prior baseline test ( include PSG ) , i.e. , hospitalization illness , breathe maskbased therapy , stable medication therapy : Stable medication define change period except within prespecified slide scale medication regimen ; If subject heart failure , baseline testing ( include PSG ) occur least 6 month initial diagnosis ; If subject systolic heart failure , baseline testing ( include PSG ) occur maximally titrate beta blocker , ACEI medication indicate current guideline ( unless contraindicate consider medically necessary ) receive indicated device therapy include device cardiac resynchronization therapy and/or primary prevention sudden cardiac death ; If subject hospitalization physician visit require IV medication screen PSG implant , subject must rescreened stable 4 . Expected tolerate study procedure opinion investigator , particular : Ability lie long enough insert remede system without shortness breath able tolerate instrumentation Polysomnogram/Polygram testing ; Expected tolerate therapy titration sensation therapy , communicate therapy experience . 5 . In investigator 's opinion , willing able comply study requirement 6 . Signed Institutional Revew Board/Medical Ethics Committee approve informed consent ( HIPAA authorization U.S. ) 1 . Pacemaker dependent subject without physiologic escape rhythm 2 . Suspected inability place catheter delivery stimulation lead ( e.g . previously know coagulopathy , distorted anatomy , prior fail pectoral implant , etc . ) 3 . Evidence phrenic nerve palsy 4 . More 2 previous open chest surgical procedure ( e.g. , CABG ) 5 . Etiology central sleep apnea know cause primarily pain medication 6 . Documented history psychosis severe bipolar disorder 7 . Cerebrovascular accident ( CVA ) within 12 month baseline test 8 . History idiopathic pulmonary hypertension , World Health Organization Class 1 9 . Limited pulmonary function either FEV1/FVC le 65 % predict value FVC le 60 % predict value 10 . Baseline oxygen saturation le 92 % awake room air 5 minute quiet rest 11 . Anticipated need chronic oxygen therapy breathe maskbased therapy 6 month post therapy initiation visit 12 . Active infection sepsis within 30 day enrollment 13 . Currently renal dialysis creatinine level great 2.5 mg/dL calculate creatinine clearance equal le 30 ml/min use CockcroftGault equation 14 . Poor liver function baseline aspartate transaminase ( AST ) , alanine transaminase ( ALT ) , and/or total bilirubin great 3 time upper limit normal ( per lab normal site ) 15 . Hemoglobin le 8 gm/dL 16 . In subject heart failure , ACC/AHA Heart Stage D 17 . Within 3 month prior baseline test , follow : uncorrected severe valvular stenosis , valve replacement repair ( percutaneous surgical ) , myocardial infarction ( MI ) , coronary artery bypass grafting ( CABG ) surgery , percutaneous coronary intervention ( PCI ) , cardiac ablation , new cardiac resynchronization device new pacemaker implant 18 . New implantable cardioverter defibrillator implantable device generator changeout within 30 day prior baseline test anticipate within first 6 month enrollment 19 . Other anticipated surgery invasive procedure expect affect ability perform test 6month posttherapy initiation visit 20 . Unstable angina 21 . Allergy intolerant contrast dye 22 . Pregnancy child bear potential without negative pregnancy test within 10 day prior remede system implant 23 . Life expectancy expect time transplant leave ventricular assist device le 12 month 24 . Currently enrol plan enroll another study may conflict protocol requirement confound subject result trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>